3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
13
Urinary Bladder Neoplasms
12
Ureteral Neoplasms
4
Neoplasm Metastasis
3
Urologic Neoplasms
2
Urogenital Neoplasms
2
Carcinoma, Renal Cell
2
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urachal adenocarcinoma
1
Salivary Gland Neoplasms
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Peripheral Nervous System Diseases
1
Penile Squamous Cell Carcinoma (PSCC)
1
Penile Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Melanoma
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma, Adenoid Cystic
1
Breast Neoplasms
1
Advanced Bladder Cancer
1
Interventions
pembrolizumab
2
darolutamide
2
relatlimab
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Surveys and Questionnaires
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Nivolumab
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
CP protocol
1
Blood Specimen Collection
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Male Urogenital Diseases
×
enfortumab vedotin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled